[Federal Register Volume 60, Number 167 (Tuesday, August 29, 1995)]
[Notices]
[Pages 44897-44898]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-21379]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 95N-0275]


Drug Export; Atenolol Bulk Drug Substance

AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that IPR 
Pharmaceuticals, Inc., a part of Zeneca Group PLC, has filed an 
application requesting approval for the export of the bulk drug 
substance Atenolol to France to produce various approved finished 
formulations containing Atenolol alone or in combination.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
human drugs under the Drug Export Amendments Act of 1986 should also be 
directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug 
Evaluation and Research (HFD-310), Food and Drug Administration, 7520 
Standish Pl., Rockville, MD 20855, 301-594-3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of drugs that 
are not currently approved in the United States. Section 802(b)(3)(B) 
of the act sets forth the requirements that must be met in an 
application for approval. Section 802(b)(3)(C) of the act requires that 
the agency review the application within 30 days of its filing to 
determine whether the requirements of section 802(b)(3)(B) have been 
satisfied. Section 802(b)(3)(A) of the act requires that the agency 
publish a notice in the Federal Register within 10 days of the filing 
of an application for export to facilitate public participation in its 
review of the application. To meet this requirement, the agency is 
providing notice that IPR Pharmaceuticals, Inc., a part of Zeneca Group 
PLC, P.O. Box 1967, Carolina, PR 00984, has filed an application 
requesting approval for the export of the bulk drug substance Atenolol 
to France. Atenolol is a synthetic, beta-selective adrenoreceptor 
blocking agent used alone or in combination with other antihypertensive 
agents. The firm has several approved applications using Atenolol from 
an approved bulk source for various finished dosage forms. The bulk 
drug substance Atenolol which is the subject of this notice will be 
manufactured in a new facility. The application was received and filed 
in the Center for Drug Evaluation and 

[[Page 44898]]
Research on July 20, 1995, which shall be considered the filing date 
for purposes of the act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by September 8, 1995, and to provide an 
additional copy of the submission directly to the contact person 
identified above, to facilitate consideration of the information during 
the 30-day review period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Drug Evaluation and Research (21 CFR 5.44).

    Dated: August 14, 1995.
Stephanie R. Gray,
Director, Office of Compliance, Center for Drug Evaluation and 
Research.
[FR Doc. 95-21379 Filed 8-28-95; 8:45 am]
BILLING CODE 4160-01-F